A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
A phase 1/2 trial of INV-8989 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer, endometrial cancer and biliary tract cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.
Overview
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations is a phase 1/2 interventional study registered as NCT07610798 by Shenzhen Ionova Life Sciences Co., Ltd., with 178 participants planned, started 2026-06-01 and due to reach its primary completion in 2029-05. Interventions recorded: INV-8989.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shares Shenzhen Ionova Life Sciences, Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialA Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TreatmentXNW27011
Shares Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.